Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
25 sept. 2024 07h30 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...
Acasti to Present at the Life Sciences Investor Forum
12 sept. 2024 08h00 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
05 sept. 2024 10h35 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
09 août 2024 08h00 HE
|
Acasti Pharma, Inc.
Surpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA...
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
27 juin 2024 16h05 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of...
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
21 juin 2024 08h00 HE
|
Acasti Pharma, Inc.
Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025Projected Cash Runway into Second Calendar Quarter 2026 ...
Acasti Pharma to Attend BIO International Convention 2024
28 mai 2024 16h05 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of...
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
12 févr. 2024 08h00 HE
|
Acasti Pharma, Inc.
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA)Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial...
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
01 févr. 2024 08h00 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine...
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
13 déc. 2023 08h00 HE
|
Acasti Pharma, Inc.
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of...